Global oncology firm Nuvation Bio Inc. NUVB on Monday revealed updated long-term data from a mid-stage trial evaluating ...

The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a ...

Sell QTTB now. The Phase 2a headline is strong, but the stock is already up ~81% and nearly 6x YTD, with RSI in the ...

Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Which news ...

On Thursday, Tevogen Bio Holdings Inc. (NASDAQ:TVGN) announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Belite Bio Inc BLTE on Monday unveiled additional secondary endpoint statistics from its ongoing Phase 3 DRAGON trial.